### ü´Ä Arrhythmias: Long QT Syndrome Diagnosis

#### ‚úÖ True Statements
1. A **QT interval** that exceeds one‚Äëhalf of the adjacent **R‚ÄëR interval** indicates **QT prolongation**.
2. When the heart rate is between 60/min and 100/min, the **corrected QT interval (QTc)** is calculated by dividing the measured QT interval by the square root of the **R‚ÄëR interval** in seconds.
3. A **QTc ‚â§440‚ÄØms in men** and **‚â§460‚ÄØms in women** is considered normal.
4. **Genetic long QT syndrome (LQTS)** is one of the most common inherited arrhythmias, occurring in approximately **1 in 1000 to 1 in 5000 persons**.
5. Clinical features suggestive of **genetic LQTS** include **syncope during sleep, auditory stimulation, or exercise** (depending on subtype), **QTc usually >460‚ÄØms**, and a propensity for **torsades de pointes**.
6. **QT prolongation** has many acquired causes, including **medications, structural heart disease, and electrolyte abnormalities**; therefore, prolonged QTc alone is insufficient to diagnose **genetic LQTS**.

#### üí¨ Extra
1. In the presented case of recurrent exertional syncope with QT prolongation on ECG, long QT syndrome is the most likely diagnosis.

#### üî∑ Tags
#Cardiology #Arrhythmias #LongQTSyndrome #QTProlongation #AmbulatoryCare #PatientUnder25

#### üìö Reference
Derived from MKSAP¬†19, Cardiovascular Medicine‚ÄîArrhythmias section.

#### üÜî Question ID
CVVDX24029

#### üïí Last Updated
February¬†2025

---

#### üìñ Related Text
MKSAP 19: Cardiovascular Medicine ‚Äî Arrhythmias, Inherited Syndromes Characterized by Sudden Cardiac Death

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. Patients **younger than 40‚ÄØyears** without ischemic or structural heart disease who experience **unexplained cardiac arrest, near‚Äëdrowning, exercise‚Äërelated syncope, or recurrent high‚Äërisk syncope** should be evaluated for **inherited arrhythmia or cardiomyopathy syndromes**.
2. **Unexplained premature death (<35‚ÄØyears)** or **sudden death (<40‚ÄØyears)** in a first‚Äëdegree relative warrants suspicion for an **inherited arrhythmia syndrome** and prompts **specialist referral with genetic counseling and testing**.
3. The diagnosis of **inherited arrhythmia syndromes** is complicated by **variable penetrance and expressivity**.
4. **Genetic LQTS** affects **1 in 1000‚Äì5000 persons**, but a **prolonged QTc (>440‚ÄØms in men, >460‚ÄØms in women) alone** is **insufficient for diagnosis** because the QT interval is variable and can be prolonged by **medications, structural heart disease, or electrolyte disturbances**.
5. Initial treatment of **genetic LQTS** includes **Œ≤‚Äëblocker therapy** and **avoidance of QT‚Äëprolonging drugs**; selected patients may require an **implantable cardioverter‚Äëdefibrillator, surgical sympathectomy, or exercise restriction**.
6. **Brugada syndrome** is identified by **‚â•2‚ÄØmm J‚Äëpoint elevation with downsloping ST‚Äësegment coving in leads V1‚ÄìV3**, occurs more frequently in persons of **Asian descent**, and is associated with **night‚Äëtime arrhythmic events and sudden cardiac death**.
7. **Hypertrophic cardiomyopathy** and **arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D)** can present as **sudden cardiac death** in young individuals; patients with ARVC/D should **avoid vigorous exercise** and those with risk factors should receive an **implantable cardioverter‚Äëdefibrillator**.
8. First‚Äëline pharmacologic therapy for **ventricular arrhythmias in ARVC/D** is a **Œ≤‚Äëblocker**; **sotalol, amiodarone,** or **catheter ablation** may be required for recurrent ventricular tachycardia.
9. **Brugada syndrome** treatment includes an **implantable cardioverter-defibrillator (ICD)**, careful avoidance or management of precipitating triggers (for example, certain drugs or fever), and **catheter ablation** in selected patients.
10. **Catecholaminergic polymorphic ventricular tachycardia (CPVT)** presents with syncope and **polymorphic or bidirectional VT** during exercise or emotional distress; optimal management involves **Œ≤-blockers, verapamil, flecainide, ICD implantation, and strict exercise abstinence**.
11. Prevention of sudden death in **hypertrophic cardiomyopathy (HCM)** may require **ICD placement, Œ≤-blockers, disopyramide, catheter ablation, or surgical myectomy**.
12. **Long QT syndrome** commonly causes syncope triggered by sleep, auditory stimuli, or exercise (depending on the genetic subtype) and is characterized by a corrected QT interval (**QTc**) usually **> 460 ms** with risk of torsades de pointes ventricular tachycardia.
13. Management of **Long QT syndrome** includes **Œ≤-adrenergic-receptor blockers (Œ≤-blockers)** and avoidance of QT-prolonging drugs; selected high-risk patients may additionally require an **implantable cardioverter-defibrillator (ICD)**, left cardiac sympathetic denervation, or exercise restriction.
14. **Brugada syndrome** presents with syncope during sleep or with ventricular fibrillation and shows a coved ST-segment elevation pattern in right-sided precordial leads **V‚ÇÅ‚ÄìV‚ÇÉ** on electrocardiogram.
15. Primary treatment for **Brugada syndrome** is ICD implantation together with avoidance‚Äîor prompt management‚Äîof precipitating factors such as fever or sodium-channel-blocking drugs; catheter ablation of the right-ventricular outflow-tract substrate may be considered in selected cases.
16. **Catecholaminergic polymorphic ventricular tachycardia (CPVT)** manifests as syncope or polymorphic/bidirectional ventricular tachycardia provoked by physical exercise or emotional distress.
17. Therapy for **CPVT** includes **Œ≤-blockers** (first-line), with possible addition of **verapamil** or **flecainide**, ICD implantation, and universal avoidance of vigorous exercise.
18. **Arrhythmogenic right-ventricular cardiomyopathy/dysplasia (ARVC/D)** may present with syncope, palpitations, T-wave inversions in leads **V‚ÇÅ‚ÄìV‚ÇÉ**, monomorphic ventricular tachycardia, frequent premature ventricular complexes, and right-ventricular structural or functional abnormalities on echocardiography or cardiac magnetic resonance imaging (**CMR**).
19. Treatment of **ARVC/D** often involves an ICD, **Œ≤-blockers**, antiarrhythmic drugs, catheter ablation, and strict avoidance of competitive or high-intensity exercise.
20. **Hypertrophic cardiomyopathy (HCM)** can present with syncope or ventricular fibrillation during exercise and is associated with increased QRS voltage with or without repolarization abnormalities on electrocardiogram.
21. Therapeutic options for **HCM** include ICD placement, **Œ≤-blockers**, **disopyramide**, septal reduction therapy via catheter ablation, and surgical myectomy.

#### üí¨ Extra
1. Evaluation typically includes ECG, cardiac imaging, and genetic testing as recommended by current guidelines.
4. QTc thresholds serve as a screening tool but are not diagnostic in isolation.
5. **Œ≤‚ÄëBlockers** blunt adrenergic surges that trigger **torsades de pointes** episodes in LQTS.
6. Fever or pharmacologic sodium‚Äëchannel blockade can unmask the Brugada ECG pattern.
9. Comprehensive evaluation for inherited arrhythmia syndromes typically includes ECG, cardiac imaging, and targeted genetic testing.
10. QTc thresholds are useful for screening but are not solely diagnostic because many acquired factors can prolong the QT interval.
11. **Œ≤-Blockers** blunt adrenergic surges that precipitate torsades de pointes episodes in long-QT syndrome.

#### üî∑ Tags
#InheritedArrhythmia #SuddenCardiacDeath #GeneticTesting #BrugadaSyndrome #ARVC #HypertrophicCardiomyopathy

---

#### üñºÔ∏è Supplemental Figures

<figure>
  <img src="ECG Showing Significant Prolongation of the QT Interval.jpg" alt="ECG showing significant QT prolongation" />
  <figcaption>ECG demonstrating significant prolongation of the QT interval, as well as abnormal morphology, which is best seen in the early precordial leads. Of note, when the heart rate is less than 60/min, the absolute QT interval is routinely used instead of the corrected QT interval (QTc) for heart rate.</figcaption>
</figure>

<figure>
  <img src="ECG Demonstrating a Type 1 Brugada Pattern.jpg" alt="ECG demonstrating a type 1 Brugada pattern" />
  <figcaption>ECG demonstrating a type 1 Brugada pattern, ‚â•2 mm J-point elevation, ST-segment coving (concave or linear downsloping ST segment) and T-wave inversions in leads V1 through V3.</figcaption>
</figure>

---

#### üóæ Supplemental Table

<!-- Inherited Syndromes Characterized by Sudden Cardiac Death -->
<table>
  <thead>
    <tr>
      <th>Disorder</th>
      <th>Presenting Symptoms and Characteristic Findings</th>
      <th>Potential Treatments<sup>a</sup></th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Long QT syndrome</td>
      <td>Syncope during sleep, auditory triggers, and/or during exercise (depending on subtype); QTc usually &gt;460&nbsp;ms; torsades de pointes</td>
      <td>&beta;-Blockers, avoidance of QT-prolonging drugs; selected patients: ICD, sympathectomy, exercise restriction</td>
    </tr>
    <tr>
      <td>Brugada syndrome</td>
      <td>Syncope during sleep, VF, coved ST-segment elevation in early precordial leads (V<sub>1</sub> through V<sub>3</sub>)</td>
      <td>ICD, avoidance or management of triggers (drugs, fever), catheter ablation</td>
    </tr>
    <tr>
      <td>Catecholaminergic polymorphic VT</td>
      <td>Syncope, polymorphic or bidirectional VT during exercise or emotional distress</td>
      <td>&beta;-Blockers, verapamil, flecainide, ICD, exercise abstinence (uniform)</td>
    </tr>
    <tr>
      <td>Arrhythmogenic right ventricular cardiomyopathy/dysplasia</td>
      <td>Syncope, palpitations, T-wave inversions in leads V<sub>1</sub> through at least V<sub>3</sub>, monomorphic VT, frequent PVCs, and abnormal right-ventricular size and function on echocardiography or CMR imaging</td>
      <td>ICD, &beta;-blockers, antiarrhythmic medications, catheter ablation, exercise abstinence (uniform)</td>
    </tr>
    <tr>
      <td>Hypertrophic cardiomyopathy</td>
      <td>Syncope, VF during exercise, increased QRS voltage with or without repolarization abnormalities on ECG</td>
      <td>ICD, &beta;-blockers, disopyramide, catheter ablation, surgical myectomy</td>
    </tr>
  </tbody>
</table>
<p><em>CMR = cardiac magnetic resonance; ICD = implantable cardioverter-defibrillator; PVC = premature ventricular contraction; QTc = corrected QT interval; VF = ventricular fibrillation; VT = ventricular tachycardia.</em></p>
<p><sup>a</sup> Treatment recommendations for ICD placement in inherited arrhythmia syndromes are guided by risk stratification with criteria that are often disease-specific. Antiarrhythmic drugs are often required for recurrent ventricular arrhythmias.</p>